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Background: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment
strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides
chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), molecular-targeted agents such as anti-angiogenic agents
(bevacizumab, aflibercept, regorafenib) and anti-epidermal growth factor receptor agents (cetuximab, panitumumab)
have become available. Ultimately, given the increasing cost of new active compounds, new strategy trials are needed
to define the optimal use and the best sequencing of these agents. Such new clinical trials require alternative
endpoints that can capture the effect of several treatment lines and be measured earlier than overall survival to
help shorten the duration and reduce the size and cost of trials.
Methods/Design: STRATEGIC-1 is an international, open-label, randomized, multicenter phase III trial designed to
determine an optimally personalized treatment sequence of the available treatment modalities in patients with
unresectable RAS wild-type mCRC. Two standard treatment strategies are compared: first-line FOLFIRI-cetuximab,
followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A) vs. first-line OPTIMOX-bevacizumab,
followed by irinotecan-based second-line chemotherapy with bevacizumab, and by an anti-epidermal growth factor
receptor monoclonal antibody with or without irinotecan as third-line treatment (Arm B). The primary endpoint is
duration of disease control. A total of 500 patients will be randomized in a 1:1 ratio to one of the two treatment
strategies.
Discussion: The STRATEGIC-1 trial is designed to give global information on the therapeutic sequences in patients
with unresectable RAS wild-type mCRC that in turn is likely to have a significant impact on the management of this
patient population. The trial is open for inclusion since August 2013.
Trial registration: STRATEGIC-1 is registered at Clinicaltrials.gov: NCT01910610, 23 July, 2013. STRATEGIC-1 is registered
at EudraCT-No.: 2013-001928-19, 25 April, 2013.
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Systemic therapy is the standard practice in unresectable
metastatic colorectal cancer (mCRC). Currently available
chemotherapy includes fluoropyrimidine, irinotecan, and
oxaliplatin either alone [1, 2] or combination [3–9]. More
recently, the combination of conventional chemotherapy
with molecular targeted therapies such as anti-vascular
endothelial growth factor (anti-VEGF) agents bevacizu-
mab (Avastin®) and aflibercept (Zaltrap®) or anti-epidermal
growth factor receptor (anti-EGFR) agents cetuximab
(Erbitux®) and panitumumab (Vectibix®) showed better
treatment outcomes in the majority of mCRC patients.
Moreover, data suggest that only patients with wild-type
Kirsten rat sarcoma viral oncogene homolog (KRAS) and
wild-type neuroblastoma RAS viral oncogene homolog
(NRAS) are likely to benefit from anti-EGFR therapy
[10–12].
Irinotecan and cetuximab
FOLFIRI (regimen of irinotecan, fluorouracil, and leucov-
orin) in combination with cetuximab is a standard first-line
regimen for patients with KRAS exon 2 wild-type tumors
based on the results of the CRYSTAL study [13]. This com-
bination yielded positive results in terms of response rate
(RR), progression-free survival (PFS), and overall survival
(OS). KRAS exon 2 wild-type tumors from CRYSTAL study
were reanalyzed for other RAS mutations in four additional
KRAS codons (exons 3 and 4) and six NRAS codons
(exons 2, 3, and 4) [14]. In patients with RAS wild-type
tumors, a significant benefit across all efficacy end points
was associated with the addition of cetuximab to FOLFIRI.
In addition, the results of the FIRE-3 study [12] confi
rmed previously reported results that first-line FOLFIRI-
cetuximab treatment achieves higher benefit in term of OS
in patients with wild-type RAS tumors [15]. Thus, patients
whose tumors lack mutations in KRAS exons 2/3/4 and
NRAS exons 2/3/4 are restricted from receiving anti-EGFR
therapy. The most active approved second-line regimen in
mCRC patients who failed initial irinotecan-based chemo-
therapy is FOLFOX-bevacizumab given until progression,
based on the survival results of an Eastern Cooperative On-
cology Group (ECOG) E3200 phase III trial [16]. The study
was positive in terms of RR, PFS, and OS.
For patients with mCRC whose disease had progressed
during second-line therapy, despite all standard thera-
peutic agents including anti-EGFR (for RAS wild-type
tumors) and anti-VEGF, regorafenib is the only approved
therapeutic option. The CORRECT study [17] showed
that regorafenib provided statistically significant benefits
in OS and PFS.
Oxaliplatin and bevacizumab
Oxaliplatin-based therapy, OPTIMOX or oxaliplatin stop-
and-go with fluoropyrimidines and FOLFOX-bevacizumab,is another standard first-line strategy based on the survival
results of the OPTIMOX1, OPTIMOX2, and NO16966
trials [18–20]. Oxaliplatin reintroduction at first pro-
gression is a part of first-line therapy in the OPTIMOX
strategy and is associated with improved survival [21].
A sensitive population with prolonged oxaliplatin-free
interval is more likely to benefit from oxaliplatin re-
introduction [22].
After tumor progression on full therapy (i.e., during
an oxaliplatin-based sequence), second-line treatment
is an irinotecan-based chemotherapy with either an anti-
angiogenic agent (bevacizumab or aflibercept), as validated
in the TML and VELOUR studies [23, 24], or an anti-
EGFR agent (cetuximab or panitumumab) based on the
results of the EPIC and ‘181’ studies [25, 26]. However
these two last studies failed to show a benefit in OS. Anti-
EGFR naïve patients who are resistant to standard chemo-
therapy can be offered cetuximab with/without irinotecan
or panitumumab alone as third-line therapy [27–29]. If
tumor progression occurs during third-line therapy, pa-
tients are exposed to all standard therapeutic agents, ex-
cept regorafenib.
Endpoints in strategy trials
The conduct of multiple-lines strategy trial requires the
establishment of alternative endpoints that can overcome
the drawbacks of OS, which remains the gold standard
outcome to validate the patient clinical benefit in the
framework of randomized clinical trials in oncology.
Measuring OS as an endpoint in clinical trials requires
a large amount of patients and long duration of follow-
up to demonstrate a statistically meaningful difference
between two or more treatments. Those specific require-
ments increase both the cost and duration of trials. In
mCRC, PFS has been validated as a surrogate for OS in
randomized clinical trial assessing first-line chemotherapy
[30–32]. This outcome is available much earlier than OS,
thus shortening the duration of trials. Moreover a smaller
sample size is required to obtain PFS and demonstrate
a statistical difference between two treatment arms. Al-
though PFS was a strong surrogate for OS when assessing
the efficacy of a single-line of treatment, the prediction
may not be as accurate for patients receiving subsequent
lines. Thus, composite endpoints such as duration of dis-
ease control (DDC) and time to failure of strategy (TFS)
have been defined and evaluated to compensate for the
disadvantages of the aforementioned endpoints [33, 34].
STRATEGIC-1- Direct comparison of both strategies
STRATEGIC-1 is a randomized trial designed to deter-
mine the best sequence of therapy in patients suffering
from mCRC and to define subsets of the population
that will benefit most from each strategy. The study
follows four successful GERCOR (Groupe Coopérateur
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best use of available drugs: the C97-1 trial that com-
pared FOLFIRI followed by FOLFOX and the reverse
sequence, the OPTIMOX1 [6], which evaluated the
concept of maintenance therapy with fluoropyrimidine
alone that is oxaliplatin stop-and-go strategy [18], the
OPTIMOX2 that examined the complete stop of chemo-
therapy [19], and the DREAM trial (OPTIMOX3) which
studied maintenance therapy with targeted agents (bevaci-
zumab +/− erlotinib) [35].Methods/Design
Primary Objective
The primary objective is to demonstrate a difference in
terms of DDC between the two treatment strategies:
FOLFIRI-cetuximab followed by an oxaliplatin-based
chemotherapy (modified FOLFOX6 [mFOLFOX6] or
modified XELOX [mXELOX]) with bevacizumab vs.
OPTIMOX-bevacizumab followed by an irinotecan-based
chemotherapy (modified FOLFIRI3 or FOLFIRI1) with
bevacizumab followed by an anti-EGFR agent (cetuximab
or panitumumab) with/without irinotecan, in patients
with unresectable wild-type RAS mCRC.Secondary Objective
The secondary objectives is to evaluate health-related
quality of life (HRQoL), OS, TFS, PFS, and RR (RECIST
v1.1) per sequence of therapy, DDC per drug, curative
salvage surgery rate (R0 or R1 resection, global and per
sequence of therapy), and safety profile of each treat-
ment sequence.Trial design
STRATEGIC-1 is an international, open-label, random-
ized, multicenter phase III trial comparing two standard
therapeutic strategies in patients with unresectable RAS
wild-type mCRC. A full list of the participating institu-
tions is displayed in Additional file 1: Table S3.Study schedule
The trial has started on August 2013. The estimated ac-
crual duration is 48 months. The estimated study com-
pletion date is December 2019 (final data collection date
for primary outcome measure). Survival status will be
collected until the patient death.Coordination
GERCOR (France) is responsible for the overall coordin-
ation and management (study documents and data qual-
ity, statistical analyses). In countries other than France
registration, management, and monitoring of centers are
delegated to a country coordinator.Ethics and regulatory considerations
This study is to be conducted in accordance with glo-
bally accepted standards of the Good Clinical Practice
(International Conference of Harmonization [ICH]-E6),
the European Directive 2001/20/EC, the latest version of
the Declaration of Helsinki, and in agreement with the
Coordinated System for gaining National Health Service
Permission (NIHR CSP) specific to France. The study
protocol was approved for all participating centers by
the French health authorities (the Agence Nationale de
Sécurité du Médicament et des Produits de Santé [ANSM]
on June 24, 2013 and the Independent Ethics Committee
“Ile de France Paris VI” La Pitié Salpêtrière on April 12,
2013) and was registered on 25 April, 2013 at EudraCT
database (EudraCT 2013-001928-19) and on 23 July, 2013
at Clinicaltrials.gov (NCT01910610). If there are any
possible future substantial amendments to the original
approved protocol, these have to be approved by the
competent authorities. This research is part of the "Ref-
erence Methodology" (MR-001) dated January 5, 2006,
relating to personal data protection. GERCOR signed a
commitment to comply with the “Reference Methodology”
regarding biomedical research and contracted civil liability
insurance to provide patients with compensation for any
injury associated with administration of the study drugs
and other aspects of the conduct of the trial.
Eligibility criteria
Inclusion criteria
 Signed and dated informed consent,
 Patients willing and able to comply with protocol
requirements,
 Age ≥ 18 years,
 Histologically proven adenocarcinoma of the colon
and/or rectum,
 Wild-type KRAS and NRAS tumor (local assessment
performed either on primary tumor or metastasis). In
exceptional circumstances, RAS (KRAS and NRAS)
mutational status may be pending consideration at
randomization provided that it is obtained within the
first two cycles of first-line therapy,
 Metastatic disease according to RECIST v1.1,
 No prior therapy for metastatic disease (in case of
previous adjuvant therapy, interval between the end
of chemotherapy and relapse must be > 6 months for
fluoropyrimidine alone or > 12 months for
oxaliplatin-, bevacizumab-, or cetuximab-based
therapy),
 Duly documented unresectable metastatic disease,
i.e., not suitable for complete carcinological surgical
resection at inclusion (patients with unresectable
disease at study entry but with any potential of
salvage surgery after induction therapy are eligible),
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assessed by computerized tomography scan (CT-scan)
or magnetic resonance imaging (MRI) according to
RECIST v1.1[36],
 ECOG Performance Status (ECOG PS) between 0
and 2,
 Hematological status: neutrophils ≥ 1.5x109/L;
platelets ≥ 100x109/L; and hemoglobin ≥ 9 g/dL,
 Adequate renal function: serum creatinine level <
150 μM,
 Adequate liver function: serum total bilirubin level ≤
1.5x upper normal limit (UNL), serum alkaline
phosphatase [ALP] level < 5xULN,
 Proteinuria < 2+ (dipstick urinalysis) or ≤ 1 g/24 h,
 Baseline evaluations performed before
randomization when wild-type RAS status is known:
clinical and blood evaluations no more than 14 days
prior to randomization, and tumor assessment (CT-
scan or MRI, evaluation of non-measurable lesions)
no more than 21 days prior to randomization,
 Reliable and appropriate methods of contraception
in childbearing potential women during the trial
and ≤ 6 months after the end of study treatments
(when applicable). Male patients with childbearing
potential partner must agree to use contraception in
addition to having their partner use another birth
control method during the trial and until ≤ 6 months
after the end of study treatments,
 Registration in France with the French National
Health Care System (including couverture maladie
universelle [CMU]).
Exclusion criteria
 Medical history or evidence of metastasis upon
physical examination of central nervous system
(CNS; e.g., non-irradiated CNS metastasis, seizure
not controlled with standard medical therapy), unless
adequately treated,
 Exclusive bone metastasis,
 Uncontrolled hypercalcemia,
 Pre-existing permanent neuropathy (National
Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) grade ≥ 2),
 Uncontrolled hypertension (defined as systolic blood
pressure > 150 mmHg and/or diastolic blood
pressure > 100 mmHg), or medical history of
hypertensive crisis, or hypertensive encephalopathy,
 Concomitant unplanned anti-tumor therapy (e.g.,
chemotherapy, molecular targeted therapy,
immunotherapy),
 Treatment with any investigational drug within
28 days prior to study entry,
 Other serious and uncontrolled non-malignant disease, Gilbert’s syndrome,
 Medical history of other concomitant or malignant
disease, except for adequately treated in-situ cervical
carcinoma, basal or squamous cell carcinoma of the
skin, and cancer in complete remission for more
than 5 years,
 Major surgical procedures (open biopsy, surgical
resection, wound revision or any other major
surgery involving entry into body cavity) or
significant traumatic injury within the last 28 days
prior to randomization, and/or minor surgical
procedure including placement of a vascular device
within 2 days of first study treatment,
 Pregnant or breastfeeding women,
 Patients with known allergy/hypersensitivity to any
component of the study drugs,
 History of arterial thrombo and/or embolic event
(e.g., myocardial infarction, stroke) within 6 months
prior to randomization,
 Chronic inflammatory bowel disease,
 Total bowel obstruction,
 History of abdominal fistula, gastrointestinal
perforation, intra-abdominal abscess or active
gastrointestinal bleeding within 6 months prior to
randomization,
 Serious, non-healing wound, active ulcer or untreated
bone fracture,
 Medical history or evidence of inherited bleeding
diathesis or significant coagulopathy at risk of
bleeding,
 Current or recent (within 10 days of randomization)
use of aspirin (> 325 mg/d), clopidogrel (> 75 mg/d),
oral anticoagulants or thrombolytic agents,
 Concomitant administration of live attenuated virus
vaccine such as yellow fever vaccine,
 Concomitant administration of prophylactic
phenytoin,
 Treatment with sorivudine or its chemically related
analogues, such as brivudine,
 Patients with known dihydropyrimidine
dehydrogenase deficiency,
 Concomitant use of St John's Wort,
 Patients with interstitial pneumonitis or pulmonary
fibrosis.
Each patient's eligibility will be verified by use of the
standardized electronic case-report form (eCRF, LIN-
COLN Technologies, France).Interventions
Patients are exposed to all validated and recognized as
standards of care agents (Fig. 1), including successive
treatment lines in the mCRC therapeutic armamentarium.
Third-line
Second-line
First-lineFOLFIRI+ Cetuximab
Irinotecan-based
+ Bevacizumab
Oxaliplatin-based
+ Bevacizumab
OPTIMOX
+ Bevacizumab
Anti-EGFR agent
+/- Irinotecan
Off-protocol. No standard option
in patients refractory to:
- Both irinotecan and
oxaliplatin,
- Both anti-angiogenic 
and anti-EGFR agents.
Arm A Arm B
Bevacizumab-
based
Anti-EGFR-
based
Oxaliplatin-
based
Irinotecan-
based
Fig. 1 STRATEGIC-1 trial schema
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may include planned/unplanned partial treatment
breaks or treatment-free interval (i.e., complete stop of
therapy), and ends with one of the following events
(whichever occurs first): disease progression occurring
on full therapy or during a partial or complete stop of
therapy without any possibility of resuming full ther-
apy. In case of progression, if the patient is not on full
therapy sequence, it should be resumed in arm B (first-
line oxaliplatin) if tolerable, and authorized in arm A
(first-line irinotecan). Patients being under RAS muta-
tional evaluation will not receive targeted therapy,
whatever treatment arm, i.e. without cetuximab in arm
A (FOLFIRI alone) and without bevacizumab in arm B
(mFOLFOX7 or mXELOX alone) for a maximum of
2 cycles.
Before switching to the planned subsequent line of
therapy, the following criteria must be fulfilled: at least
one reason to discontinue previous line of therapy,
patient general conditions compatible with treatment
continuation (at investigator’s discretion), and accept-
able residual toxicities from previous line of therapy.Arm A (Figure 1, Table 1)
First-line
First-line treatment consists of fortnightly FOLFIRI-
cetuximab until progression or unacceptable toxicity.Second-line
Second-line treatment consists of a fortnightly oxaliplatin-
based chemotherapy (mFOLFOX6 or mXELOX) with
bevacizumab until disease progression or unacceptable
toxicity. The occurrence of disease progression or un-
acceptable toxicity during second-line therapy defines the
end of treatment strategy in arm A.Arm B (Figure 2 and 3, Table 2)
First-line
First-line treatment consists of a fortnightly oxaliplatin-
based chemotherapy (mFOLFOX7 or mXELOX) with
bevacizumab as induction therapy during 3 months
(6 cycles), followed by a maintenance therapy with
fluoropyrimidine (simplified LV5FU2 regimen or cape-
citabine) and bevacizumab until disease progression. A
chemotherapy-free interval (CFI) is allowed after at least
3 months of maintenance therapy (at investigator’s discre-
tion) for patients fulfilling the following criteria: controlled
disease (i.e., absence of tumor progression), duration of
chemotherapy ≥ 6 months after starting induction treat-
ment, baseline platelet count < 400.000/mm3, and nor-
mal carcinoembryonic antigen (CEA) level at first or
second evaluation after starting induction therapy. In
case of progression occurring 3 months or later after
the last administration of oxaliplatin and in absence of
residual neuropathy, maintenance therapy should be
Table 1 Treatment regimens in Arm A
A. Doses in FOLFIRI-cetuximab regimen
H0 Cetuximab 400 mg/m2 /2 h IV infusion (first dose), then
250 mg/m2 /1 h at subsequent IV infusions, every week
or
Cetuximab 500 mg/m2 /2 h IV infusion (first dose), then
500 mg/m2 /1 h at subsequent IV infusions, every 2 weeks
H + 1 Irinotecan 180 mg/m2, in 500 ml NaCl 0.9 % solution, 1 h IV
infusion
Folinic acid 400 mg/m2 (leucovorin, racemic or L-form
200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min
IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
B. Doses in modified FOLFOX6-bevacizumab
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 85 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Folinic acid 400 mg/m2 (racemic, or L-form 200 mg/m2) in
250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min
IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
C. Doses in modified XELOX-bevacizumab
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 85 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Day 1-8 Capecitabine 1250–1500 mg/m2 bid, from day 1 (in the
evening) to day 8 (in the morning)
Cycles every 2 weeks, until disease progression, unacceptable toxicity or
withdrawal of consent
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early progression (i.e., occurring less than 3 months
after the last administration of oxaliplatin) and/or re-
sidual neuropathy contra-indicating oxaliplatin reintro-
duction, maintenance therapy should be followed by
second-line therapy.
Second-line
Second-line treatment consists of irinotecan-based chemo-
therapy (mFOLFIRI3 or FOLFIRI1) with bevacizumab until
disease progression or unacceptable toxicity. Frail patients
(ECOG PS > 2 and/or total serum bilirubin > 3xUNL) are
allowed to receive an anti-EGFR agent alone (cetuximab or
panitumumab).
Third-line
At the end of second-line therapy, patients receive
cetuximab with or without irinotecan or panitumumab
until disease progression or unacceptable toxicity. The
occurrence of disease progression during third-line ther-
apy defines the end of treatment strategy in arm B. If
the patient remains eligible for reintroduction of anoxaliplatin-based chemotherapy (i.e., no prior progression
during FOLFOX or XELOX and residual neuropathy
grade ≤ 2), the end of treatment strategy is defined at the
date of progression after this reintroduction.
General considerations for dose modifications
Toxicities should be graded according to the NCI CTCAE
v4.0 [37]. For toxicities considered by the investigator un-
likely to develop into serious or life-threatening events
(e.g., alopecia, altered taste), treatment should be contin-
ued at the same dose without reduction or interruption.
In addition, no dose reductions or interruptions are
required for anemia (non-hemolytic) as this can be satis-
factorily managed by transfusions and/or erythropoiesis-
stimulating agent. If several toxicities with different grades
or severities occur at the same time, dose modifications
should be done according to the greatest reduction applic-
able. If toxicity is considered to be due solely to one of the
drugs (e.g., hand-foot syndrome secondary to fluoropyri-
midines, neurotoxicity due to oxaliplatin, hypertension
and proteinuria due to bevacizumab, acne-like syndrome
due to cetuximab or panitumumab), other drugs do not
require a dose adjustment. Dosage adjustment for isolated
abnormal lab values should be based on parameters at
start of a treatment cycle (or one working day before).
Based on the most severe toxicity experienced since the
last treatment, the scheduled treatment rest period should
be extended until all toxicities subside to grade 1 or less.
Salvage surgery
Secondary surgery of metastases is authorized providing
that the following conditions are respected: prior assess-
ment of tumor response (i.e., at least one tumor evaluation
after randomization) and intent to achieve a complete sur-
gical resection (R0). In case of R0 or R1 resection, the use
of a postoperative treatment and choice of the therapeutic
regimen are left to the investigator’s discretion. Yet,
FOLFOX is recommended in both arms. In case of R2
resection, the patient resumes the therapeutic strategy
according to allocated treatment arm.
Study endpoints
The primary endpoint is DDC, defined as the sum of PFS
of each active treatment course planned in the therapeutic
strategy (i.e., no disease progression at the first evaluation
from the start of the sequence) [33]. DDC excludes in-
active sequence (i.e., disease progression at the first tumor
evaluation) and intervals between disease progression and
re-initiation of treatment (either reintroduction in the
stop-and-go strategy or subsequent course of treatment in
the planned multi-line strategy). Censoring rules for DDC
are: the end of study with no signs of progression or
addition of a new (unplanned) therapeutic agent. Patients
Maintenance and/or CFI
(until PD or toxicity)
Reintroduction
mFOLFOX7* - bevacizumab 
6 cycles (3 months)
Induction
mFOLFOX7* - Bevacizumab 
6 cycles (3 months)
Early progression
(< 3 months from end of oxaliplatin)
and/or residual neuropathy (grade >1)
Late progression
(≥ 3 months from end of oxaliplatin)
and no residual neuropathy (grade ≤1) 
Eligibility criteria for oxaliplatin 
reintroduction
1/ Interval between the end of oxaliplatin and PD
2/ Residual neuropathy
PD at first evaluation
(2 months)
Maintenance
Fluoropyrimidine - Bevacizumab 
[sLV5FU2 or capecitabine]
(until PD or toxicity)
End of first-line therapy
*Or mXELOX
Fig. 2 First-line OPTIMOX strategy in arm B
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for DDC.
Secondary endpoints include HRQoL, OS, TFS, PFS,
and RR (RECIST v1.1) per sequence of therapy, DDC
per drug, curative salvage surgery rate (R0 or R1 resection,
global and per sequence of therapy), and safety profile of
each treatment sequence according to the NCI CTCAE.
HRQoL is assessed using the European Organization for
Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire (QLQ-C30). HRQoL will be considered
to be improved if at least one time to HR-QoL score
deterioration (five targeted dimensions) is significantly
longer without a significant shorter time to HRQoL score
deterioration for other four-targeted dimensions (single
sufficient design). Time to HRQoL score (global health,
fatigue, pain, physical and emotional functioning) deteri-
oration will be compared between the two arms [38, 39].
Overall survival is defined as the time interval from
randomization to the date of death from any cause. Alive
patients will be censored at the last date known to bealive, either during study treatment period or during
follow-up period. PFS is defined as the time interval
from randomization to the date of first documented
disease progression or death from any cause, whichever
occurs first. Alive patients without progression will be
censored at the last tumor assessment, either during
study treatment period or during follow-up period. TFS
is defined as the total PFS from the initiation of the
strategy to the first of the following events: 1) death, 2)
disease progression on the last received planned sequence,
3) patient requiring the addition of a new (unplanned)
therapeutic agent, and 4) disease progression during a
partial or complete break in therapy.
Sample size
The following hypotheses are considered for primary
analyses with two-sided type I error (alpha) of 5 %:
under the null hypothesis (H0), DDC of the two treatment
arms is equal (HR Arm A/ Arm B = 1) while under the alter-
native hypothesis (H1), DDC of the two treatment arms is
End of first-line therapy
ECOG PS 
Serum bilirubin level
ECOG PS 0-2
And bilirubin ≤ 3xULN 
ECOG PS > 2 
and/or bilirubin > 3xULN 
Irinotecan-based chemotherapy
with bevacizuamb
(until PD or toxicity)
Anti-EGFR agent
(until PD or toxicity)
ECOG PS 0-2
And bilirubin ≤ 3xULN 
ECOG PS > 2 
and/or bilirubin > 3xULN
Anti-EGFR agent + 
Irinotecan
(until PD or toxicity)
Anti-EGFR agent
(until PD or toxicity)
End of strategy 
End of strategy 
If improvement 
(ECOG PS ≤ 2 and 
bilirubin ≤ 3 x ULN), 
irinotecan +/- 5FU 
may be introduced
Second-line therapy
Third-line therapy
Fig. 3 Second- and third-line strategies in arm B
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for testing the primary variable DDC with a two-sided
type I error (alpha) of 5 % and a type II error (beta) of
10 % (Software: EAST 5.3) and two planned interim ana-
lyses (to reject H0 or H1, Alpha Spending Function and
O’Brien and Fleming Boundaries). A 33 % reduction in
the risk of event (HR = 0.67) is assumed under the H1 in
arm B. This reduction is estimated based on an absolute
gain of 8 months for median DDC (from 16 months in
arm A to 24 months in arm B) and on an assumed ex-
ponential distribution of the DDC curves. In order to
observe 264 events required for the type I and II error,
450 patients will be determined for study enrolment.
Besides, it is anticipated that 10 % of patients will be in-
cluded without complete RAS mutational status available
at randomization therefore it is foreseen that RAS muta-
tion will be present in 50 % of those after randomization
or will be still unknown 1 month after randomization,
resulting in their exclusion. It is therefore necessary to in-
clude additional 5 % of patients. Assuming an additional
5 % dropout rate, for other reasons, 50 patients will beadded in order to reach the necessary power for a statis-
tical comparison of the DDC curves, resulting in a total of
500 patients needed to be recruited. The number of ran-
domized patients with RAS mutated tumors or unknown
RAS mutational status after two cycles of first-line therapy
will be reviewed at the time of interim analyses. Two
interim analyses will be performed after the inclusion of
150 and 385 patients without interrupting patient accrual.
In arm A, the expected median DDC is 16 months,
with median PFS of 10 months for first-line treatment
(FOLFIRI-cetuximab) and 6 months for second-line ther-
apy (FOLFOX-bevacizumab). In arm B, the targeted me-
dian DDC is 24 months, with median PFS of 9 months for
induction therapy, median PFS from reintroduction of
3 months (taking into account a reintroduction rate of
70 %), median second-line PFS of 7 months, and median
third-line PFS of 5 months.
In regard to HRQoL, the aim is to obtain sufficient
statistical power to improve median time to HRQoL score
deterioration from 4 months [40] to 6 months to be con-
sidered as clinically relevant (Hazard Ratio [HR] = 0.67). A
Table 2 Treatment regimens in Arm B
A. Doses in modified FOLFOX7-bevacizumab
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 100 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Folinic Acid 400 mg/m2 (leucovorin, racemic or L-form
200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU continuous infusion 3000 mg/m2, 46 h IV infusion
B. Doses in modified XELOX-bevacizumab regimen
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 100 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Day 1-8 Capecitabine 1250–1500 mg/m2 bid, day 1 (in the
evening) to day 8 (in the morning)
C. Doses in simplified LV5FU2-bevacizumab regimen
H0 Bevacizumab 5 mg/kg, 30 min IV infusion
H + 1 Folinic acid 400 mg/m2 (leucovorin, racemic or L-form
200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution,
15 min IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
D. Doses in capecitabine-bevacizumab regimen
H0 Bevacizumab 7.5 mg/kg, 30 min IV infusion
Day 1-14 Capecitabine 1000 mg/m2 x twice daily (on days 1 to 14;
28 doses)
E. Doses in modified FOLFIRI3-bevacizumab regimen
H0 (Day 1) Bevacizumab 5 mg/kg, 30 min IV infusion
H + 1 Irinotecan 90 mg/m2 in 250 ml glucose 5 %, 1 h IV
infusion
Folinic Acid 400 mg/m2 (leucovorin, racemic or L-form
200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
H + 46
(Day 3)
Irinotecan 90 mg/m2, 1 h IV infusion
F. Doses in FOLFIRI1-bevacizumab regimen
H0 Bevacizumab 5 mg/kg, 30 min IV infusion
H + 1 Irinotecan 180 mg/m2 in 250 ml glucose 5 %, 1 h IV
infusion
Folinic acid 400 mg/m2 (leucovorin, racemic or L-form
200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution,
15 min IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
G. Doses in cetuximab +/− irinotecan regimen
H0 Cetuximab, 400 mg/m2 /2 h IV infusion (first dose), then
250 mg/m2 /1 h at subsequent IV infusions, every week
or
Cetuximab 500 mg/m2 /2 h IV infusion (first dose), then
500 mg/m2 /1 h at subsequent IV infusions, every 2 weeks
H + 1 Irinotecan 180 mg/m2 in 250 ml glucose 5 %, 1 h IV
infusion (optional)
H. Dose of panitumumab monotherapy
H0 Panitumumab, 6 mg/kg, 1 h IV infusion, every 2 weeks
a. b Cycles every 2 weeks, during 6 cycles (3 months). c. Cycles every 2 weeks,
until disease progression, CFI, unacceptable toxicity or withdrawal of consent.
d. Cycles every 3 weeks, until disease progression, CFI, unacceptable toxicity or
withdrawal of consent. e. Cycles every 2 weeks, until disease progression,
unacceptable toxicity or withdrawal of consent. f. Cycles every 2 weeks, until
disease progression, unacceptable toxicity or withdrawal of consent. g.
Cetuximab every 1 or 2 weeks, until disease progression, unacceptable toxicity
or withdrawal of consent. h. Cycles every two weeks, until disease progression,
unacceptable toxicity or withdrawal of consent
Chibaudel et al. BMC Cancer  (2015) 15:496 Page 9 of 13bilateral alpha type I error of 0.01 % (Bonferoni adjust-
ment for multiple comparisons) and a power of 90 % are
targeted in order to take into account the five compari-
sons (one for each score). To observe the 363 required
events it will be necessary to have at least 1 month of
follow-up among randomized patients. If only 375 patients
have available score (83 %), the minimal follow-up will be
16 months.
Randomization: sequence generation
An unblinded randomization with a 1:1 ratio is done
using a minimization technique. Random allocation se-
quence is generated through a computer random num-
ber generator. Patients are stratified on the following
parameters: center, the GERCOR prognostic score based
on ECOG PS and serum lactate dehydrogenase (LDH)
level (low vs. intermediate vs. high risk group) [41], prior
use of oxaliplatin in adjuvant setting (yes vs. no), and
extension of metastatic disease (liver only vs. other).
The minimization algorithm takes into account already
randomized patients in order to allocate a new treat-
ment. A subgroup of patients who present the same
stratification variables that the patient to be randomized
is isolated. The total number of patients in that subgroup
is counted by stratification variables and treatment group.
A less represented treatment group is selected by the
system and attributed to the patient. The randomization
result provided by the system is attributed in 80 % of the
cases; otherwise the other treatment is attributed.
Implementation of randomization
All investigators and on-site clinical research associates
are provided with unique user names and passwords in
order to access, review, and approve the eCRFs. Once
randomization is started, the allocated arm appears on
the randomization form and a confirmation email is sent
to all members of the investigational site and of GER-
COR. From then on, the randomization form is frozen
and can no longer be modified.
Statistical analysis
The statistical analysis plans (final and dedicated to
HRQoL analyses) will be agreed and written before the
database is frozen.
The modified (m) intent-to-treat (ITT) 1 population
for efficacy analyses includes all randomized patients
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to the treatment group allocated by randomization.
Patients for whom RAS mutational status (wild-type or
mutated) is available after 2 cycles will not be included
in the analyses. This population is the primary popula-
tion for all efficacy parameters (except HRQoL).
The mITT2 population that includes patients belong-
ing to the mITT1 population with at least one QLQ-C30
completed at baseline will be used for HRQoL analyses.
The safety population (all patients who received at least
one dose of any planned study treatment) will be used
for reporting the safety and treatment exposure data.
Selected efficacy analyses will be repeated in the per-
protocol (PP) population (i.e., subset of the mITT1
population meeting the following criteria: all eligibility
criteria fulfilled, at least one dose of allocated treatment
administered, and RAS wild-type tumor confirmed after
central assessment).
All tests will be performed at a two-sided 5 % signifi-
cance level with the exception of tests for the primary
endpoint for which a Lan-DeMets alpha spending func-
tion with O’Brien and Fleming boundaries (function de-
pending on the information fraction in the ITT population)
will be used. The nominal significance levels for the interim
and final analyses of DDC will be derived from the later
function.
All tests in HRQoL analyses will be performed at a
two-sided 1 % significance level. If confidence intervals
(CIs) are to be calculated, those will be at a two-sided
95 % CI and a nominal (1-alpha) 100 % CI for all primary
endpoints.
Continuous Variables
Continuous variables will be summarized using descrip-
tive statistics, i.e. number of patients with available data
(n), mean, median, standard deviation (SD), 25 %-75 %
quartile (Q1-Q3), minimum, and maximum. Continuous
variables could be transformed to categorical variables
using the median or using conventional cut-offs from
bibliography or clinical practice.
Categorical Variables
Frequencies in tables will be presented by arm, total fre-
quency, percentages, and missing modality. Qualitative
variables will be summarized by means of counts and
percentages. Unless otherwise stated, the calculation of
proportions will be based on the sample size of the
population of interest.
Time to Event Variables
Kaplan Meier curves will be used to describe event-free
rates over time. Median event-free times by treatment
arm will be reported with 95 % CIs, if the number of
events allows the estimation of the median. Confidenceinterval of median survival time will be calculated ac-
cording to Brookmeyer and Crowley[42]. Event rates at
specified time points will be estimated from the Kaplan-
Meier curve. The standard error will be estimated by the
Greenwood formula and the log-log transformation will
be used to compute CIs. The treatment effects will be
summarized by means of a HR derived from a Cox pro-
portional hazard model with its associated 95 % CI.
Follow-up
Follow-up will be estimated using the reverse Kaplan-
Meier method, and will be described using the median
with its 95 % CI.
Survival
Survival will be estimated using the Kaplan-Meier method,
and will be described using the median with its 95 % CI.
Univariate Cox proportional hazard model will be used to
estimate HR (control arm vs. investigational arm) with
95 % CI. Multivariate Cox analysis will be done. A univariate
selection procedure will serve to identify eligible explana-
tory variables with univariate Cox (using Wald Test)
p-value lower than 0.10 as potential prognostic value.
Pre-specified subgroup analysis
The goal of the pre-specified subgroups analyses is to
confirm consistency of the impact of the arm B strategy
on DDC.
Methodology
Pre-specified subgroups are defined as follows:
 Stratification factors: center, the GERCOR prognostic
score, prior use of oxaliplatin in adjuvant setting,
extension of metastatic disease (liver only vs. other),
 Patient characteristics:
– Demographic: age (< 65 vs. ≥ 65), sex (male vs.
female), countries (in case of multinational
participation),
– Baseline characteristics: ECOG PS (0 vs. 1 vs. 2),
prior hypertension, number of metastatic sites (1
vs. > 1), disease confined to liver (yes vs. no),
location of primary tumor (colon vs. rectum vs.
both), synchronous vs. metachronous disease,
prior adjuvant chemotherapy (yes vs. no), LDH
level (normal vs. > 1xULN), ALP level (normal
vs. > 1-3xULN vs. > 3-5xULN), serum CEA level
(normal vs. > 1-10xULN vs. > 10-100xULN vs. >
100xULN), white blood cell [WBC] count
(< 10,000/mm3 vs. ≥ 10,000/mm3), and platelets
(< 400,000/mm3 vs. ≥ 400,000/mm3),
– Demographic: age (< 65 vs. ≥ 65), sex (male vs.
female), countries (in case of multinational
participation),
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prior hypertension, number of metastatic sites
(1 vs. > 1), disease confined to liver (yes vs. no),
location of primary tumor (colon vs. rectum vs.
both), synchronous vs. metachronous disease,
prior adjuvant chemotherapy (yes vs. no), LDH
level (normal vs. > 1xULN), ALP level (normal
vs. > 1-3xULN vs. > 3-5xULN), serum CEA level
(normal vs. > 1-10xULN vs. > 10-100xULN vs. >
100xULN), white blood cell [WBC] count
(< 10,000/mm3 vs. ≥ 10,000/mm3), and platelets
(< 400,000/mm3 vs. ≥ 400,000/mm3),
 Reintroduction rate of FOLFOX-bevacizumab in
arm B (global and per center: < 40 % vs. 40 %-50 %
vs. 50 %-60 % vs. ≥ 60 %).
Analyses
Association between pre-specified subgroups and sur-
vival will be explored using univariate Cox analysis for
all parameters. The continuous variables will be treated
as quantitative and qualitative data using cut-off in an-
ticipation of elaborating a practical clinical tool. Propor-
tional hazard assumption will be graphically assessed.
Factors will be considered for inclusion in the model
as potentially associated with DDC and OS if the univar-
iate p-value is ≤ 0.1.
The Cox regression model will be used for multivariate
analysis of prognostic factors for DDC and OS.
Interactions between treatment and each subgroup
will be tested at a two-sided 10 % level (i.e., a p-value >
0.1 indicates no evidence of heterogeneity of treatment
effect across the subgroups for each factor).
Within each subgroup, the treatment effect HR and its
(1-α) % CI will be estimated using a Cox proportional
hazard model on patients of this subgroup.
Translational research
Tumor tissue and peripheral blood samples will be col-
lected at several time points for translational research.
Those samples will be used to discover and validate
prognostic and predictive markers of response to anti-
EGFR agents and to evaluate relationship between key
angiogenic markers and clinical outcome parameters.
Prospectively collected biological material from either
primitive tumor or metastatic disease will be stored until
the end of patients’ accrual. All tumors will be character-
ized by the most frequent tumor genes alterations
(including KRAS, BRAF, NRAS, PIK3CA, APC, SMAD4,
FBXW7, and any prognostic and predictive relevant
genes) using deep sequencing at the end of enrolment.
Whole blood samples will be drawn for subsequent
extraction of DNA and RNA from lymphocytes and
plasma. Samples will be collected in both arms before
cycles 1 and 2 of first-line treatment and in arm B beforecycles 1 and 2 of third-line treatment. A systematic
translational projects with 1) validation of the micro
RNA hsa-mir-31-3p as a marker of efficacy of cetuximab
[43], 2) estimation of the prognostic and the predictive
role of circulating tumor DNA at the time of inclusion,
and 3) evaluation of differences in tumor circulating
DNA between cycles 1 and 2 of treatment will be per-
formed. DNA extracted from tumors will be used to
characterize the most frequent mutations.
Discussion
The increasing number of new therapeutic options
provides more complicated treatments algorithms in pa-
tients with unresectable mCRC. Therefore, randomized
strategy trials are indispensable to compare many pos-
sible treatment options in clinical practice and to make
the best strategy choice that can be formally recommend
in this setting. Although several randomized first-line
trials (FIRE-3[12], PEAK[44], CALGB8503[45]) were de-
signed to evaluate chemotherapy with anti-VEGF and
anti-EGFR agents, the subsequent lines of treatment in
these studies were not fixed and crossover was likely to
pose an obstacle to prediction of OS.
Conclusion
STRATEGIC-1 phase III study has been designed to
seek for the optimal treatment sequence to be used as
standard practice strategy for RAS wild-type mCRC. The
trial is based on the concept of a central symmetry that
is comparing two planned therapeutic multiple-line
strategies each including all the currently available
chemotherapy and molecular targeted agents, but in a
different order. Besides, the trial aims to identify patient
population that would benefit the most from anti-EGFR
and anti-VEGF therapy. The study has started in July
2013 in France. The trial will be available to participants
in other countries in the near future.
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